Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects

Inclusion Criteria: * Healthy males, or non-pregnant, non-lactating healthy females either of non-child bearing potential, or taking an approved method of contraception for the duration of the study * Age 18 to 55 years of age, inclusive * Non-smoking subjects with body weight ≥45 kg * Body mass index (BMI) of 18 to 32 kg/m2 (inclusive) * Must be willing and able to communicate and participate in the whole study * Must provide written informed consent * Must agree to use an adequate method of contraception Exclusion Criteria: * Participation in a clinical research study within the previous 3 months * Subjects who are study site employees, or immediate family members of a study site or sponsor employee * Subjects who have previously been enrolled in this study * History of any drug or alcohol abuse in the past 2 years * History of regular alcohol consumption within 6 months of the study (male subjects \>21 units per week or female subjects \>14 units per week; 1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine) * Positive alcohol breath test * Current smokers and those who have smoked within the last 6 months. A breath carbon monoxide reading of greater than 10 ppm at screening * Females of childbearing potential who are pregnant or lactating (female subjects must have a negative urine pregnancy test at admission) * Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening * Clinically significant abnormal biochemistry, haematology or urinalysis * Positive drugs of abuse test result * Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results * Positive genotyping test * History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease as judged by the investigator * Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients * Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active * Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period * Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than hormone replacement therapy \[HRT\]/hormonal contraception not containing ethinyl estradiol) or herbal remedies in the 14 days before IMP administration * Significant medical history of fainting or vasovagal attacks * History of uncontrolled or poorly controlled hypertension * Semi-supine systolic BP \<90 mmHg or \>140 mmHg, or diastolic BP \>100 mmHg after 3 assessments * QTcB or QTcF of \>450 msec in male subjects or \>470 msec in females * Presence or history of any clinically significant abnormality in vital signs or ECG * Presence of any medical condition, which in the opinion of the investigator may interfere with the study procedures or compromise subject safety * Medical history of clinically significant depression * History of suicide attempt within 6 months prior to screening * History of acute porphyria * History of cardiac conduction disorders with the exception of 1st degree heart block * Mentally or legally incapacitated * Unwillingness or inability to follow the procedures outlined in the protocol, or to comply with study restrictions on smoking, concomitant medications and diet * Failure to satisfy the investigator of fitness to participate for any other reason